Iterum Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results on November 12, 2021
November 05 2021 - 7:00AM
Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a
clinical-stage pharmaceutical company focused on developing next
generation oral and IV antibiotics to treat infections caused by
multi-drug resistant pathogens in both community and hospital
settings, today announced that the Company will release its
third quarter 2021 financial results before the open of
the U.S. financial markets on Friday, November 12,
2021. Management will host a conference call at 8:30 a.m.
ET that day to discuss the Company’s financial results and
provide an update on its business.
To access the call please dial 844-200-6205
(domestic) or 929-526-1599 (international) and refer to Access Code
442364. The audio webcast can be accessed under “Financials &
Filings” in the Investors section of the Company’s website at
www.iterumtx.com following the call.
About Iterum Therapeutics
plc
Iterum Therapeutics plc is a clinical-stage
pharmaceutical company dedicated to developing differentiated
anti-infectives aimed at combatting the global crisis of multi-drug
resistant pathogens to significantly improve the lives of people
affected by serious and life-threatening diseases around the world.
Iterum is currently advancing its first compound, sulopenem, a
novel penem anti-infective compound, in Phase 3 clinical
development with an oral formulation. Sulopenem also has an IV
formulation. Sulopenem has demonstrated potent in vitro activity
against a wide variety of gram-negative, gram-positive and
anaerobic bacteria resistant to other antibiotics. Iterum has
received Qualified Infectious Disease Product (QIDP) and Fast Track
designations for its oral and IV formulations of sulopenem in seven
indications. For more information, please
visit http://www.iterumtx.com.
Forward-Looking Statements
This press release contains forward-looking
statements. These forward-looking statements include, without
limitation, statements regarding the development, therapeutic and
market potential of sulopenem. In some cases, forward-looking
statements can be identified by words such as “may,” “believes,”
“intends,” “seeks,” “anticipates,” “plans,” “estimates,” “expects,”
“should,” “assumes,” “continues,” “could,” “would,” “will,”
“future,” “potential” or the negative of these or similar terms and
phrases. Forward-looking statements involve known and unknown
risks, uncertainties and other factors that may cause the Company’s
actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements.
Forward-looking statements include all matters that are not
historical facts. Actual future results may be materially different
from what is expected due to factors largely outside the Company’s
control, including uncertainties inherent in the initiation and
conduct of clinical and non-clinical development, including any
additional trials that may be conducted in response to the Complete
Response Letter received by the Company in July 2021, availability
and timing of data from such clinical and non-clinical development,
changes in regulatory requirements or decisions of regulatory
authorities, the timing or likelihood of regulatory filings and
approvals, including the potential resubmission of a new drug
application for sulopenem etzadroxil/probenecid, changes in public
policy or legislation, commercialization plans and timelines, if
oral sulopenem is approved, the actions of third-party clinical
research organizations, suppliers and manufacturers, the accuracy
of the Company’s expectations regarding how far into the future the
Company’s cash on hand will fund the Company’s ongoing operations,
the impact of COVID-19 and related responsive measures thereto,
risks and uncertainties concerning the outcome, impact, effects and
results of the Company’s evaluation of corporate, strategic,
financial and financing alternatives, including the terms, timing,
structure, value, benefits and costs of any corporate, strategic,
financial or financing alternative and the Company’s ability to
complete one at all and other factors discussed under the caption
“Risk Factors” in its Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission (the “SEC”) on August 13, 2021,
and other documents filed with the SEC from time to time.
Forward-looking statements represent the Company’s beliefs and
assumptions only as of the date of this press release. Except as
required by law, the Company assumes no obligation to update these
forward-looking statements publicly, or to update the reasons
actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future.
Investor Contact:Judy
MatthewsChief Financial Officer 312-778-6073IR@iterumtx.com
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From Apr 2023 to Apr 2024